Sector News

Siegfried buys BASF drug ingredient businesses for $306 million

May 7, 2015
Chemical Value Chain
(Reuters) – German chemicals group BASF has agreed to sell parts of its pharmaceutical ingredients business to Swiss drug contract manufacturer Siegfried Holding for 270 million euros ($306 million), including assumed debt.
 
“Siegfried will reach the critical size to play a leading role in the supplier market as a recognized partner for the pharmaceutical industry,” said Siegfried Chief Executive Rudolf Hanko.
 
Siegfried said financing of the transaction was secured by a syndicate of Swiss banks and there were no plans for a capital increase. It plans to issue a hybrid bond for partial refinancing after completion of the deal.
 
BASF said on Thursday the move was part of a strategy to focus its pharmaceutical ingredients business on excipients, which are auxiliary pharmaceutical ingredients that help the body to better absorb a drug.
 
BASF will keep selected active ingredients such as ibuprofen, omega-3 fatty acids and polyethylene glycol (PEG), where the company has a leading market position.
 
(Reporting by Ludwig Burger; Editing by Hugh Lawson)

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

Ineos and Hyundai announce collaboration surrounding hydrogen economy

Chemical Value Chain

Hyundai and INEOS will jointly investigate opportunities for the production and supply of hydrogen, as well as the worldwide deployment of hydrogen applications and technologies.

November 27, 2020

Partnership to develop AI technologies for industry

Chemical Value Chain

Wood and industrial software company Cognite have partnered to accelerate industrial transformation by creating AI technologies that will allow heavy-asset infrastructure and industry to achieve more connected, sustainable, and data-driven operations.

November 27, 2020

Shell launches ‘blue’ hydrogen technology

Chemical Value Chain

Shell Catalysts & Technologies, which licenses technologies and brings capabilities to market, has launched Shell Blue Hydrogen Process, aimed to significantly increase the affordability of greenfield “blue” hydrogen projects.

Send this to a friend